London, July 20 /PRNewswire/ -- There has been a recent upsurge in Merger & Acquisition (M&A) activities in the pharmaceutical and biotechnology space. While the economic downturn and related credit crunch has had an impact, this alone cannot account for the recent M&A mania, which has including four mega M&As in the first half of 2009.
"The real intention behind these mergers remains a question, as past mergers have not yielded substantial value addition in terms of R&D productivity," says Frost & Sullivan Senior Research Analyst Ranjith Gopinathan.
To look at these Mergers & Acquisitions in the Pharmaceutical and Biotechnology industry, the Healthcare Group at Frost & Sullivan will be hosting a complimentary Analyst Briefing Presentation on Tuesday, 28th July 2009, at 2 p.m. BST/ 1 p.m. GMT.
Highlights of this briefing will include an analysis of the factors contributing to the increasing consolidation in the market, the impact of the economic downturn, as well as funding sources for biotech companies. The briefing will also look at key restraints for M&A activities in the pharma-biotech industry and provide a future M&A outlook. The discussion will benefit venture capitalists, investment banks, pharma and biotech companies as well as academic institutions.
"The global downturn's detrimental impact on funding availability coupled with an average 30 per cent decline in the value of biotech firms, means that outright acquisitions rather than complex licensing deals are an attractive proposition," concludes Gopinathan.
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved